Enliven Therapeutics Ownership | Who Owns Enliven Therapeutics?

Enliven Therapeutics Ownership Summary

Enliven Therapeutics is owned by 38.69% institutional investors, 5.56% insiders, and 55.75% retail investors. Orbimed advisors is the largest institutional shareholder, holding 15.28% of ELVN shares.

ELVN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Enliven Therapeutics	38.69%	5.56%	55.75%
Sector	Healthcare Stocks	279.42%	10.64%	-190.05%
Industry	Biotech Stocks	64.05%	10.69%	25.27%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Orbimed advisors	7.96M	15.28%	$159.67M
Commodore capital lp	4.67M	9.38%	$92.00M
Vr adviser	4.03M	7.73%	$80.77M
Fairmount funds management	3.71M	7.12%	$74.45M
Polar capital	3.05M	5.85%	$61.19M
Blackrock funding, inc. /de	2.97M	5.69%	$59.52M
Point72 asset management	1.35M	2.60%	$27.14M
Blackstone	1.32M	2.53%	$26.49M
Capital research global investors	1.32M	2.52%	$26.39M
Novo	1.08M	2.08%	$21.75M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Fairmount funds management	3.71M	9.65%	$74.45M
Commodore capital lp	4.67M	6.78%	$92.00M
Vr adviser	4.03M	6.05%	$80.77M
Ally bridge group (ny)	281.39K	4.70%	$5.64M
Orbimed advisors	7.96M	4.00%	$159.67M
Caxton	13.10K	2.67%	$262.74K
First turn management	535.09K	2.12%	$10.53M
Patient square capital lp	245.84K	1.78%	$4.93M
Novo	1.08M	1.54%	$21.75M
Tcg crossover management	498.00K	1.14%	$9.99M

Top Buyers

Holder	Shares	% Assets	Change
Capital research global investors	1.32M	0.01%	1.32M
Point72 asset management	1.35M	0.05%	1.21M
Novo	1.08M	1.54%	1.08M
Polar capital	3.05M	0.32%	685.00K
Blackstone	1.32M	0.11%	558.28K

Top Sellers

Holder	Shares	% Assets	Change
Adage capital partners gp	96.00K	0.00%	-354.00K
Ikarian capital	-	-	-289.54K
Acuta capital partners	-	-	-265.27K
Lord, abbett	-	-	-197.28K
Nicholas investment partners, lp	-	-	-157.63K

New Positions

Holder	Shares	% Assets	Change	Value
Capital research global investors	1.32M	0.01%	1.32M	$26.39M
Novo	1.08M	1.54%	1.08M	$21.75M
Tcg crossover management	498.00K	1.14%	498.00K	$9.99M
Candriam s.c.a.	416.65K	0.05%	416.65K	$8.36M
Affinity asset advisors	400.00K	1.10%	400.00K	$8.02M

Sold Out

Holder	Change
Td capital management	-16.00
Stephens consulting	-20.00
Amundi	-23.00
Clear street markets	-76.00
Srs capital advisors	-103.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	14	-87.27%	19,292,189	-60.47%	38	0.38%	5	-92.19%	3	-88.00%
Dec 31, 2024	112	9.80%	49,623,714	4.06%	102	1.05%	66	11.86%	25	4.17%
Sep 30, 2024	102	8.51%	47,688,348	-1.31%	98	0.98%	59	-14.49%	24	84.62%
Jun 30, 2024	94	30.56%	48,320,278	8.69%	100	0.90%	69	72.50%	13	-40.91%
Mar 31, 2024	72	18.03%	44,456,336	13.99%	105	1.18%	40	29.03%	22	69.23%

Recent Insider Transactions

Date	Name	Role	Activity	Value
Aug 07, 2025	Patel Anish	CHIEF OPERATING OFFICER	Sell	$113.95K
Aug 07, 2025	Patel Anish	CHIEF OPERATING OFFICER	Sell	$7.67K
Jul 28, 2025	Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sell	$1.38K
Jul 28, 2025	Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sell	$65.12K
Jul 21, 2025	Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Sell	$13.19K

Insider Transactions Trends

Date	Buy	Sell
2025 Q3	-	10
2025 Q2	-	28
2025 Q1	-	14
2024 Q4	-	34
2024 Q3	-	27

ELVN Ownership FAQ

Who Owns Enliven Therapeutics?

Enliven Therapeutics shareholders are primarily institutional investors at 38.69%, followed by 5.56% insiders and 55.75% retail investors. The average institutional ownership in Enliven Therapeutics's industry, Biotech Stocks , is 64.05%, which Enliven Therapeutics falls below.

Who owns the most shares of Enliven Therapeutics?

Enliven Therapeutics’s largest shareholders are Orbimed advisors (7.96M shares, 15.28%), Commodore capital lp (4.68M shares, 9.38%), and Vr adviser (4.03M shares, 7.73%). Together, they hold 32.38% of Enliven Therapeutics’s total shares outstanding.

Does Blackrock own Enliven Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Enliven Therapeutics.

Who is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested?

Fairmount funds management is Enliven Therapeutics’s biggest shareholder by percentage of total assets invested, with 9.65% of its assets in 3.71M Enliven Therapeutics shares, valued at 74.45M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools